| Objective To inquire the current situation of the rational use of recombinant human granulocyte colony stimulating factor(rhG-CSF)in a hospital,we investigated the rational use of rhG-CSF in patients with gynecological malignant tumors in the hospital from 2017 to 2018,and compared the irrational use of rhG-CSF in 2017 with 2018 after intervention by clinical pharmacists.This paper summarized and analyzed the results of the survey,and gave suggestions to provide a reference for promoting the rational use of rhG-CSF in this hospital.Methods By searching the latest guidelines about regular use of recombinant human granulocyte colony stimulating factor published at home and abroad,the rational criteria for evaluating the use of rhG-CSF in gynecological patients in the hospital were scientifically and rationally sorted out,and a questionnaire for case collection was developed accordingly.According to the inclusion criteria,patients' basic characteristics,disease diagnosis and medication information were obtained from the medical record and filled into the questionnaire one by one.A database was established according to the unified criteria and the computer was used for unified analysis.After the intervention by clinical pharmacists in the hospital through the guidance interpretation,prescription comments,pharmaceutical ward rounds and other means,the unreasonable medication situation in 2017 and 2018 were analyzed and compared.Results The results showed that a total of 365 patients met the inclusion criteria,including 208 patients in 2017 and 157 patients in 2018 respectively.The departments involved mainly included: radiotherapy department,gynecology department,and medical oncology.There is a wide range of irrational utilization of the rhG-CSF.Among all investigated cases,the use problems of rhG-CSF was mainly identified in the following four aspects,including unsuitable medicated purpose,71.63%(149/208)in 2017 and 63.06(99/157)in 2018;incorrectly delivery time,11.06%(23/208)in 2017 and 13.38%(21/157)in 2018;inadequacy dose of rhG-CSF,98.56%(205/208)in 2017 and 84.71%(133/157)in 2018;false withdrawl timing,32.69%(68/208)in 2017 and 26.75%(42/157)in 2018.Conclusion Irrational utilization of rhG-CSF is common in patients with gynecological malignant tumors in this hospital.After intervention by clinical pharmacists,the unreasonable rate of dosage,the medicated purpose and withdrawal timing decreased,but delivery time were not improved.On one hand,clinicians are lack of knowledge about the rational use of rhG-CSF,so it is necessary to further study the latest guidelines of rhG-CSF.On the other hand,clinical pharmacists should give full play to their functions,popularize pharmaceutical information to clinicians on a regular basis,provide the best medication plan for clinicians,and intervene against unreasonable medical application timely.In addition,the medical insurance department and the quality control department should participate in the supervision of the rational use of rhG-CSF together. |
PDF Full Text Request